Multi-arm Polymer Prodrugs for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering small molecule therapeutics, particularly oncolytics like camptothecin derivatives, face challenges such as poor aqueous solubility, rapid hydrolysis, severe side effects, high clearance rates, and limited tumor permeation, leading to reduced efficacy and increased toxicity.
Innovation Solution
Development of multi-arm water-soluble polymer prodrugs with three or more active agents covalently attached to a polymer via hydrolyzable linkages, allowing for controlled release and improved bioavailability, bioactivity, and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule therapeutics are administered directly, then they exhibit high bioactivity, but they suffer from poor aqueous solubility, rapid hydrolysis, and high clearance rates
Solution Approach 1:
A multi-arm water-soluble polymer serves as an intermediary carrier that covalently attaches multiple small molecule therapeutics through hydrolyzable linkages. The polymer protects the therapeutics from rapid clearance and hydrolysis while maintaining their bioactivity through controlled release mechanisms.
Solution Approach 2:
The invention creates a composite prodrug structure combining water-soluble polymer material with hydrophobic small molecule therapeutics. This composite approach resolves the solubility issue while preserving therapeutic efficacy through the hydrolyzable linkage design.
2Object-affected harmful factors
If conventional drug delivery approaches are used, then they address some delivery challenges, but they result in severe side effects and limited tumor permeation
Solution Approach 1:
The therapeutic payload is segmented into multiple copies attached to separate polymer arms, enabling controlled distribution and release. This segmentation allows the drug to permeate tumor tissue more effectively while reducing systemic side effects through localized action.
Solution Approach 2:
The invention changes the molecular parameters of the therapeutic by attaching it to a polymer backbone, altering its pharmacokinetic properties including tumor permeation capability and side effect profile while maintaining the core therapeutic mechanism.
3Quantity of substance
If multiple active agents are attached to a polymer, then drug loading efficiency is improved, but the complexity of characterizing the conjugate increases
Solution Approach 1:
The polymer conjugate exhibits local quality heterogeneity with multiple identical therapeutic units attached to uniform polymer arms. This structured heterogeneity allows for systematic characterization approaches that account for the multi-component nature while maintaining reproducibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-arm polymer prodrugs demonstrate enhanced tumor growth suppression, increased tumor retention time, reduced adverse side effects, and improved pharmacokinetics compared to unmodified drugs, effectively addressing the limitations of existing delivery methods.
Implementation Method 1
covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents attached, preferably releasably, to a water soluble polymer. In one embodiment, each of the arms of the water soluble polymer possesses an active agent covalently attached thereto, preferably by a hydrolyzable linkage.
Data Source
AI summary
Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.